Supplementary Materials

Supplementary Material for:

Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica

Fumitaka Shimizu, Kristin L. Schaller, Gregory P. Owens, Anne C. Cotleur, Debra Kellner, Yukio Takeshita, Birgit Obermeier, Thomas J. Kryzer, Yasuteru Sano, Takashi Kanda, Vanda A. Lennon, Richard M. Ransohoff,* Jeffrey L. Bennett*

*Corresponding author. Email: richard.ransohoff{at}biogen.com (R.M.R.); bennett{at}ucdenver.edu (J.L.B.)

Published 5 July 2017, Sci. Transl. Med. 9, eaai9111 (2017)
DOI: 10.1126/scitranslmed.aai9111

This PDF file includes:

  • Fig. S1. Effects of IgG from NMO or SLE patients or healthy controls on the activation of and binding to BMECs.
  • Fig. S2. Binding of IgG from NMO or SLE patients or healthy controls to human astrocytes expressing AQP4 or human astrocytes.
  • Fig. S3. Effect of NMO-IgG or NMO-rAb on BMEC activation.
  • Fig. S4. Binding of NMO-IgG or NMO-rAb to human astrocytes expressing AQP4 or human astrocytes.
  • Fig. S5. Effects of non-AQP4 NMO-rAb on other MECs.
  • Fig. S6. Target of rAb ON-12-2-46 is widely expressed at both the cellular and tissue level.
  • Fig. S7. GRP78 expression on MECs in vitro and in vivo.
  • Fig. S8. Effect of commercial GRP78 Abs on BMEC activation.
  • Table S1. Effect of serum IgG from each patient with NMO and SLE and healthy controls on BMEC activation.
  • Table S2. Effect of pooled IgG and 14 rAbs from NMO patients and healthy controls on BMEC activation.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 Primary data (Microsoft Excel format).